Cognitive impairment in patients with chronic cerebral ischemia (discirculatory encephalopathy)

Chronic cerebral ischemia (CCI), also known as discirculatory encephalopathy (DE), is one of the most common diagnoses in Russian neurological practice. In patients diagnosed with CCI or DE, assessing cognitive function (CF) is essential for distinguishing between individuals with and without cognitive impairment (CI). If CI is present in a patient with CCI or DE, comorbid Alzheimer's disease (AD) or other neurodegenerative disorders affecting CF should be considered. Neuropsychological assessment (identifying amnestic syndrome) and MRI of the brain (evidence of hippocampal atrophy) can raise suspicion for AD, with definitive diagnosis relying on detection of biological markers of the disease. Unfortunately, many patients with AD are long misdiagnosed with CCI or DE and thus do not receive appropriate treatment. Patients with a diagnosis of CCI or DE and preserved CF often suffer from other neurological or psychiatric disorders, most frequently anxiety-depressive disorders, primary headaches (tension-type headache, migraine, medication-overuse headache), peripheral vestibulopathy, or persistent postural-perceptual dizziness. Managing patients with CI requires controlling vascular risk factors, preventing stroke, applying psychosocial interventions, and encouraging household, social, physical, and intellectual activity. In the dementia stage, cognitive function may be improved by central acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the glutamate receptor antagonist memantine. The efficacy and safety of choline alfoscerate in patients with AD and cerebrovascular disease are also discussed.

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6.

2. Parfenov VA, Zaharov VV, Preobrazhenskaja IS. Cognitive disorders. Moscow: Remedium; 2014 (In Russ.)].

3. Parfenov VA, Koberskaya NN. Alzheimer'sdisease. Moscow: IMA-PRESS; 2022 (In Russ.)].

4. Mok VCT, Cai Y, Markus HS. Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions. Int J Stroke. 2024 Oct;19(8):838-56. doi: 10.1177/17474930241279888

5. Gottesman RF, Schneider AL, Zhou Y, et al. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA. 2017 Apr 11;317(14):1443-50. doi: 10.1001/jama.2017.3090

6. Iadecola C, Duering M, Hachinski V, et al. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Jul 2;73(25):3326-3344. doi: 10.1016/j.jacc.2019.04.034

7. Dhana K, Agarwal P, James BD, et al. Healthy Lifestyle and Cognition in Older Adults With Common Neuropathologies of Dementia. JAMA Neurol. 2024 Mar 1;81(3):233-9. doi: 10.1001/jamaneurol.2023.5491

8. Parfenov VA. Discirculatory encephalopathy and vascular cognitive disorders. Moscow: IMA-PRESS; 2017 (In Russ.)].

9. Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.

10. Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):412. doi: 10.14412/2074-2711-2021-1-4-12 (In Russ.)].

11. Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction – The disregarded partner of Alzheimer's disease. Alzheimer's Dement. 2019;15:158-6. doi: 10.1016/j.jalz.2018.07.222

12. Jack CR Jr, Bennett DA, Blennow K, et al;Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-62. doi: 10.1016/j.jalz.2018.02.018

13. Dubois B, Villain N, Frisoni GB, et al.Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021 Jun;20(6):484-96. doi: 10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29.

14. Parfenov VA, Grishina DA, Tyurina AYu. Alzheimer's disease: diagnosis and treatment, errors in patient management. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):95100. doi: 10.14412/2074-2711-2024-2-95-100 (In Russ.)].

15. Shevtsova KV, Rozhkov DO, Grishina DA, et al. Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(3):96-102. doi: 10.14412/2074-2711-2024-3-96-102 (In Russ.)].

16. Caplan L. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture-2000. Stroke. 2000 Aug;31(8):2011-23. doi: 10.1161/01.str.31.8.2011

17. Olesen J, Bes A, Kunkel R, et al; Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658

18. Parfenov VA. Management of patients with cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):97-102. doi: 10.14412/2074-2711-2023-1-97-102 (In Russ.)].

19. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-734. doi: 10.1016/S01406736(17)31363-6. Epub 2017 Jul 20.

20. Chalfont G, Milligan C, Simpson J.A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020 May;19(4):1086-130. doi: 10.1177/1471301218795289. Epub 2018 Sep 7.

21. Van den Brink AC, Brouwer-Brolsma EM,Berendsen AAM, van de Rest O. The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer's Disease – A Review. Adv Nutr. 2019 Nov 1;10(6):1040-65. doi: 10.1093/advances/nmz054

22. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S01406736(15)60461-5. Epub 2015 Mar 12.

23. Salzman T, Sarquis-Adamson Y, Son S, et al. Associations of Multidomain Interventions With Improvements in Cognition in Mild Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022 May 2;5(5):e226744. doi: 10.1001/jamanetworkopen.2022.6744.

24. Yaffe K, Vittinghoff E, Dublin S, et al. Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. JAMA Intern Med. 2024 Jan 1;184(1):54-62. doi: 10.1001/jamainternmed.2023.6279

25. Cummings J, Osse AML, Cammann D, et al. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2024 Jan;38(1):5-22. doi: 10.1007/s40259-023-00633-2. Epub 2023 Nov 13.

26. Jönsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023 May 22;29:100657. doi: 10.1016/j.lanepe.2023.100657

27. Sims JR, Zimmer JA, Evans CD, et al;TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512-27. doi: 10.1001/jama.2023.13239

28. Perneczky R, Dom G, Chan A, et al. Anti-amyloid antibody treatments for Alzheimer's disease. Eur J Neurol. 2024 Feb;31(2):e16049. doi: 10.1111/ene.16049. Epub 2023 Sep 11.

29. Cocchiara RA, De Lucia F, Koci L, et al.Management of the early stage of Alzheimer's disease: a systematic review of literature over the past 10 years. Clin Ter. 2020 JulAug;171(4):e357-e368. doi: 10.7417/CT.2020.2239

30. Barbagallo Sangiorgi G, Barbagallo M,Giordano M, et al. alphaGlycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. 1994 Jun 30;717:253-69. doi: 10.1111/j.1749-6632.1994.tb12095.x

31. Scapicchio PL. Revisiting cholinealphoscerate profile: a new, perspective, role in dementia? Int J Neurosci. 2013 Jul;123(7):444-9. doi: 10.3109/00207454.2013.765870. Epub 2013 Feb 19.

32. Amenta F, Carotenuto A, Fasanaro AM, etal. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results. J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

33. Carotenuto A, Rea R, Traini E, et al. The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. J Alzheimers Dis. 2017;56(2):805-15. doi: 10.3233/JAD-160675

34. Carotenuto A, Fasanaro AM, Manzo V, et al. Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer's Disease. J Alzheimers Dis Rep. 2022 May 23;6(1):235-43. doi: 10.3233/ADR-200269

35. Traini E, Carotenuto A, Fasanaro AM, Amenta F. Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial. J Alzheimers Dis. 2020;76(1):317-29. doi: 10.3233/JAD-190623

36. Lee W, Kim M. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. Medicine (Baltimore). 2024 Jun 14;103(24):e38067. doi: 10.1097/MD.0000000000038067

37. Carotenuto A, Andreone V, Amenta F, Traini E. Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial. Medicina (Kaunas). 2024 Jun 1;60(6):925. doi: 10.3390/medicina60060925